- Clinical characteristics and univariate analysis of 32 patients with diffuse large B-cell lymphoma of the breast.
| Variables | All (n=32) | 5 years progression-free survival | 5 years overall survival | ||
|---|---|---|---|---|---|
| Precentages | P-values | Precentages | P-values | ||
| Age at diagnosis | 59.13±13.27 | ||||
| ≥60 years | 18 (56.3) | 81% | 0.629 | 81% | 0.738 |
| <60 years | 14 (43.7) | 55% | 63% | ||
| Gender | |||||
| Male | 1 (3.1) | -- | -- | -- | -- |
| Female | 31 (96.9) | ||||
| Primary site | |||||
| Left | 14 (43.8) | 69% | 0.171 | 68% | 0.129 |
| Right | 16 (50.0) | 80% | 82% | ||
| Bilateral | 2 (6.2) | 50% | 50% | ||
| Tumor size | 4.15±2.64 | ||||
| ≥5 cm | 13 (40.6) | 74% | 0.129 | 72% | 0.172 |
| <5 cm | 19 (59.4) | 66% | 67% | ||
| Ann-Arbor stage | |||||
| III-IV | 13 (40.6) | 61% | 0.047* | 61% | 0.031* |
| I-II | 19 (59.4) | 75% | 71% | ||
| IPI score | |||||
| 3-5 score | 26 (81.2) | 67% | 0.445 | 67% | 0.360 |
| 0-2 score | 6 (18.8) | 71% | 72% | ||
| B symptoms | |||||
| Yes | 7 (21.9) | 52% | 0.084 | 52% | 0.026* |
| No | 25 (78.1) | 78% | 79% | ||
| Pathological diagnosis | |||||
| GCB | 7 (21.9) | 100% | 0.164 | 100% | 0.110 |
| Non-GCB | 25 (78.1) | 64% | 60% | ||
| Metastasis | |||||
| Yes | 20 (62.5) | 64% | 0.235 | 62% | 0.204 |
| No | 12 (37.5) | 88% | 89% | ||
| Recurrence | |||||
| Yes | 11 (34.4) | 30% | <0.001* | 40% | 0.001* |
| No | 21 (65.6) | 100% | 100% | ||
| Outcome | |||||
| Alive | 26 (81.3) | -- | -- | -- | -- |
| Die | 6 (18.7) | ||||
| Comorbidities | |||||
| Yes | 25 (78.1) | 69% | 0.468 | 69% | 0.457 |
| No | 7 (21.9) | 73% | 73% | ||
| Insulin (uU/ml) | 10.54±6.10 | -- | -- | -- | -- |
| FPG (mmol/L) | 5.93±2.50 | -- | -- | -- | -- |
| HOMA-IR | 2.45±0.74 | ||||
| >2.7 | 18 (56.2) | 63% | 0.864 | 66% | 0.885 |
| ≤2.7 | 14 (43.8) | 78% | 79% | ||
Values are presented as numbers and prescentages (%).
↵* P-value of <0.05 was significant. IPI: international prognostic index, GCB: germinal center B-cell, FPG: fasting plasma glucose, HOMA-IR: homeostasis model assessment of insulin resistance